Latest Lpath Inc (LPTN) Headlines Nasdaq stoc
Post# of 39
Posted On: 03/10/2014 11:29:35 AM
Latest Lpath Inc (LPTN) Headlines
Nasdaq stocks posting largest volume increases
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
New Published Paper Shows Efficacy of Lpath's Anti-LPA Antibody, Lpathomab, in Traumatic Brain Injury Models
PR Newswire - Wed Mar 05, 6:30AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has brought scientists one step closer to finding a potential treatment for traumatic brain injury (TBI) with a recent publication showing that Lpathomab(TM), a therapeutic antibody, reverses much of the damage caused by trauma to the nervous system.
Lpath to Present at Upcoming Roth Investor Conference
PR Newswire - Tue Mar 04, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, today announced that Scott Pancoast, president and CEO, will be presenting at the 26th Annual Roth Conference being held March 10 -12, 2014 in Laguna Niguel, Calif. Mr. Pancoast is scheduled to present on March 11, 2014 at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be webcast live and will be available for replay on the Lpath, Inc. corporate website at www.Lpath.com.
Lpath announces receipt of key US patent related to its ocular drug programme
M2 - Thu Jan 23, 5:03AM CST
Lpath Inc (Nasdaq:LPTN), a provider of bioactive lipid-targeted therapeutics, announced on Wednesday the receipt of official notification from the US Patent and Trademark Office that it has been issued another key patent supporting its iSONEP programme.
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP
PR Newswire - Wed Jan 22, 6:30AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office that the company has been issued another key patent supporting its iSONEP(TM) program. The newly issued U.S. patent, No. 8,614,103, is entitled, "Compositions and Methods for Treating Ocular Conditions." It claims methods of using monoclonal antibodies (including iSONEP) that bind sphingosine-1-phosphate (S1P) in the treatment of a wide variety of ocular conditions, including wet age-related macular degeneration (AMD).
FEPSGA Games - Herbalist, Others Enjoy Trade Boom in Makurdi
All Africa Global Media - Wed Dec 18, 4:41AM CST
A herbalist selling traditional medicines at the venue of the ongoing Federal Public Service Games Association (FEPSGA) Games in Makurdi says he is enjoying high patronage.
Global Pulmonary Fibrosis Pipeline Review Report - H2 2013 Edition Now Available
M2 - Tue Dec 17, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqb72k/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Pulmonary Fibrosis Therapeutics Development - Eli Lilly and Company - Lpath, Inc. - Mesoblast Ltd - NicOx SA - Oncothyreon Inc - Pharmaxis Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Aquinox Pharmaceuticals Inc. - Angion Biomedica Corp. - Centocor Ortho Biotech, Inc. - Fibrotech Therapeutics Pty. Ltd. - FCB-Pharmicell Co.,Ltd. - Clarassance, Inc. Drug Profiles - Lpathomab - P-17 - AZX-100 - PX-866 - STNM-04 - P-529 - AQX-1125 - Btx-201 - GR-MD-02 - ICG-001 - CG-1011 - ANG-3298 - C-201 - Galectin-3 Inhibitors - SDP-051 - FT-011 - CT-140 - PDE-4A4 Inhibitors - NCX-466 - MC-1575 - Lungcellgram - CpG Oligonucleotides - PXS-5033-A For more information visit http://www.researchandmarkets.com/research/cqb72k/pulmonary
Lpath Withdraws From Pfizer's Process to Assign iSONEP Rights
PR Newswire - Thu Dec 12, 6:00AM CST
Lpath, Inc. (Nasdaq: LPTN), the category leader in lipid-targeted therapeutics, is no longer actively participating in Pfizer's process to assign the exclusive option it has for a worldwide license to develop and commercialize Lpath's iSONEP(TM). Pfizer has informed Lpath that its offers were not competitive with other offers.
Lpath Announces New Antibody Program, Altepan(TM), Targeting Respiratory Disease
PR Newswire - Thu Nov 21, 6:00AM CST
Lpath, Inc. (Nasdaq: LPTN), the category leader in lipid-targeted therapeutics, has used its proprietary discovery technology to generate several monoclonal antibody product candidates targeting the leukotriene family of bioactive lipids. Leukotrienes are implicated in numerous inflammatory processes. The lead antibody, which binds to and neutralizes several different leukotriene isoforms, has shown positive in vivo results, and testing in animal models of respiratory disease, including asthma, is now underway.
Choroidal Neovascularization - Pipeline Review, H2 2013
M2 - Fri Nov 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/wqgmkj/choroidal) has announced the addition of the "Choroidal Neovascularization - Pipeline Review, H2 2013" report to their offering. 'Choroidal Neovascularization - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Choroidal Neovascularization, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Choroidal Neovascularization. This analysis is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Choroidal Neovascularization. - A review of the Choroidal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Choroidal Neovascularization pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Choroidal Neovascularization. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Choroidal Neovascularization pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Choroidal Neovascularization Overview Therapeutics Development Companies Involved in Choroidal Neovascularization Therapeutics Development Drug Profiles - ranibizumab - ranibizumab - iSONEP - aflibercept - RX-20001 - RX-10008 - PGN-635 - KH-902 - MAT-302 - PRM-167 - Drug For Ocular Diseases - rCD59-APT542 - SK-1011 - sterculic acid Featured News & Press Releases Appendix Companies Mentioned - Affitech A/S - F. Hoffmann-La Roche Ltd. - Lpath, Inc. - Mat Biopharma - Promedior, Inc. - Regeneron Pharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Sanwa Kagaku Kenkyusho Co.,Ltd For more information visit http://www.researchandmarkets.com/research/wqgmkj/choroidal
Diabetic Neuropathy - Pipeline Review, H2 2013
M2 - Wed Oct 09, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9bgwcx/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H2 2013" report to their offering. 'Diabetic Neuropathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy. Scope - A snapshot of the global therapeutic scenario for Diabetic Neuropathy. - A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Neuropathy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Takeda Pharmaceutical Company Limited Dong-A Pharmaceutical Co., Ltd. Neuralstem, Inc. Lpath, Inc. DiaMedica Inc. R-Tech Ueno, Ltd. Neurotune AG Intellect Neurosciences, Inc. Glucox Biotech Vascular Pharmaceuticals, Inc. TheraQuest Biosciences, LLC For more information visit http://www.researchandmarkets.com/research/9bgwcx/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lpath Provides Update on Plans for iSONEP Option
PR Newswire - Tue Oct 08, 3:30PM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive-lipid-targeted therapeutics, has received notice from Pfizer Inc. that Pfizer is currently seeking to divest certain ophthalmology R&D assets, including Pfizer's exclusive option for a worldwide license to develop and commercialize Lpath's iSONEP(TM). Lpath has presented an offer to Pfizer to reacquire these rights, and Lpath believes that a number of third parties may have an interest in acquiring these rights as well.
Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - Lpath, Inc., (NASDAQ: LPTN)
WorldStockWire - Fri Aug 30, 12:15AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Nasdaq stocks posting largest percentage increases
AP - Mon Jul 29, 5:27PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Lpath to Present at the 2013 JMP Healthcare Conference on July 9
Marketwire - Wed Jul 03, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive-lipid-targeted therapeutics, today announced that it will participate in the JMP Securities Healthcare Conference in New York, taking place July 9-10, 2013. President and Chief Executive Officer Scott R. Pancoast will give his presentation on Tuesday, July 9, 2013 at 2:30 p.m. EDT (11:30 a.m. PDT). He will discuss the company's pathway to regulatory approval and commercialization of its novel therapeutics, including its anti-S1P antibody iSONEP(TM) which, in partnership with Pfizer, is being studied in the Phase 2 Nexus Study as a potential treatment for wet AMD.
Nasdaq stocks posting largest volume increases
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
New Published Paper Shows Efficacy of Lpath's Anti-LPA Antibody, Lpathomab, in Traumatic Brain Injury Models
PR Newswire - Wed Mar 05, 6:30AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has brought scientists one step closer to finding a potential treatment for traumatic brain injury (TBI) with a recent publication showing that Lpathomab(TM), a therapeutic antibody, reverses much of the damage caused by trauma to the nervous system.
Lpath to Present at Upcoming Roth Investor Conference
PR Newswire - Tue Mar 04, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, today announced that Scott Pancoast, president and CEO, will be presenting at the 26th Annual Roth Conference being held March 10 -12, 2014 in Laguna Niguel, Calif. Mr. Pancoast is scheduled to present on March 11, 2014 at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be webcast live and will be available for replay on the Lpath, Inc. corporate website at www.Lpath.com.
Lpath announces receipt of key US patent related to its ocular drug programme
M2 - Thu Jan 23, 5:03AM CST
Lpath Inc (Nasdaq:LPTN), a provider of bioactive lipid-targeted therapeutics, announced on Wednesday the receipt of official notification from the US Patent and Trademark Office that it has been issued another key patent supporting its iSONEP programme.
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP
PR Newswire - Wed Jan 22, 6:30AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office that the company has been issued another key patent supporting its iSONEP(TM) program. The newly issued U.S. patent, No. 8,614,103, is entitled, "Compositions and Methods for Treating Ocular Conditions." It claims methods of using monoclonal antibodies (including iSONEP) that bind sphingosine-1-phosphate (S1P) in the treatment of a wide variety of ocular conditions, including wet age-related macular degeneration (AMD).
FEPSGA Games - Herbalist, Others Enjoy Trade Boom in Makurdi
All Africa Global Media - Wed Dec 18, 4:41AM CST
A herbalist selling traditional medicines at the venue of the ongoing Federal Public Service Games Association (FEPSGA) Games in Makurdi says he is enjoying high patronage.
Global Pulmonary Fibrosis Pipeline Review Report - H2 2013 Edition Now Available
M2 - Tue Dec 17, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqb72k/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Pulmonary Fibrosis Therapeutics Development - Eli Lilly and Company - Lpath, Inc. - Mesoblast Ltd - NicOx SA - Oncothyreon Inc - Pharmaxis Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Aquinox Pharmaceuticals Inc. - Angion Biomedica Corp. - Centocor Ortho Biotech, Inc. - Fibrotech Therapeutics Pty. Ltd. - FCB-Pharmicell Co.,Ltd. - Clarassance, Inc. Drug Profiles - Lpathomab - P-17 - AZX-100 - PX-866 - STNM-04 - P-529 - AQX-1125 - Btx-201 - GR-MD-02 - ICG-001 - CG-1011 - ANG-3298 - C-201 - Galectin-3 Inhibitors - SDP-051 - FT-011 - CT-140 - PDE-4A4 Inhibitors - NCX-466 - MC-1575 - Lungcellgram - CpG Oligonucleotides - PXS-5033-A For more information visit http://www.researchandmarkets.com/research/cqb72k/pulmonary
Lpath Withdraws From Pfizer's Process to Assign iSONEP Rights
PR Newswire - Thu Dec 12, 6:00AM CST
Lpath, Inc. (Nasdaq: LPTN), the category leader in lipid-targeted therapeutics, is no longer actively participating in Pfizer's process to assign the exclusive option it has for a worldwide license to develop and commercialize Lpath's iSONEP(TM). Pfizer has informed Lpath that its offers were not competitive with other offers.
Lpath Announces New Antibody Program, Altepan(TM), Targeting Respiratory Disease
PR Newswire - Thu Nov 21, 6:00AM CST
Lpath, Inc. (Nasdaq: LPTN), the category leader in lipid-targeted therapeutics, has used its proprietary discovery technology to generate several monoclonal antibody product candidates targeting the leukotriene family of bioactive lipids. Leukotrienes are implicated in numerous inflammatory processes. The lead antibody, which binds to and neutralizes several different leukotriene isoforms, has shown positive in vivo results, and testing in animal models of respiratory disease, including asthma, is now underway.
Choroidal Neovascularization - Pipeline Review, H2 2013
M2 - Fri Nov 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/wqgmkj/choroidal) has announced the addition of the "Choroidal Neovascularization - Pipeline Review, H2 2013" report to their offering. 'Choroidal Neovascularization - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Choroidal Neovascularization, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Choroidal Neovascularization. This analysis is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Choroidal Neovascularization. - A review of the Choroidal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Choroidal Neovascularization pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Choroidal Neovascularization. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Choroidal Neovascularization pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Choroidal Neovascularization Overview Therapeutics Development Companies Involved in Choroidal Neovascularization Therapeutics Development Drug Profiles - ranibizumab - ranibizumab - iSONEP - aflibercept - RX-20001 - RX-10008 - PGN-635 - KH-902 - MAT-302 - PRM-167 - Drug For Ocular Diseases - rCD59-APT542 - SK-1011 - sterculic acid Featured News & Press Releases Appendix Companies Mentioned - Affitech A/S - F. Hoffmann-La Roche Ltd. - Lpath, Inc. - Mat Biopharma - Promedior, Inc. - Regeneron Pharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Sanwa Kagaku Kenkyusho Co.,Ltd For more information visit http://www.researchandmarkets.com/research/wqgmkj/choroidal
Diabetic Neuropathy - Pipeline Review, H2 2013
M2 - Wed Oct 09, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9bgwcx/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H2 2013" report to their offering. 'Diabetic Neuropathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy. Scope - A snapshot of the global therapeutic scenario for Diabetic Neuropathy. - A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Neuropathy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Takeda Pharmaceutical Company Limited Dong-A Pharmaceutical Co., Ltd. Neuralstem, Inc. Lpath, Inc. DiaMedica Inc. R-Tech Ueno, Ltd. Neurotune AG Intellect Neurosciences, Inc. Glucox Biotech Vascular Pharmaceuticals, Inc. TheraQuest Biosciences, LLC For more information visit http://www.researchandmarkets.com/research/9bgwcx/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lpath Provides Update on Plans for iSONEP Option
PR Newswire - Tue Oct 08, 3:30PM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive-lipid-targeted therapeutics, has received notice from Pfizer Inc. that Pfizer is currently seeking to divest certain ophthalmology R&D assets, including Pfizer's exclusive option for a worldwide license to develop and commercialize Lpath's iSONEP(TM). Lpath has presented an offer to Pfizer to reacquire these rights, and Lpath believes that a number of third parties may have an interest in acquiring these rights as well.
Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - Lpath, Inc., (NASDAQ: LPTN)
WorldStockWire - Fri Aug 30, 12:15AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Nasdaq stocks posting largest percentage increases
AP - Mon Jul 29, 5:27PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Lpath to Present at the 2013 JMP Healthcare Conference on July 9
Marketwire - Wed Jul 03, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive-lipid-targeted therapeutics, today announced that it will participate in the JMP Securities Healthcare Conference in New York, taking place July 9-10, 2013. President and Chief Executive Officer Scott R. Pancoast will give his presentation on Tuesday, July 9, 2013 at 2:30 p.m. EDT (11:30 a.m. PDT). He will discuss the company's pathway to regulatory approval and commercialization of its novel therapeutics, including its anti-S1P antibody iSONEP(TM) which, in partnership with Pfizer, is being studied in the Phase 2 Nexus Study as a potential treatment for wet AMD.
(0)
(0)Lpath Inc. (LPTN) Stock Research Links
Scroll down for more posts ▼